Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 202   

Articles published

SNY 51.76 +0.22 (0.43%)
price chart
DRug Active runners: Pfizer Inc. (NYSE:PFE), Sanofi SA (ADR) (NYSE:SNY ...
Sanofi SA (ADR) (NYSE:SNY) seems to be in for a bumpy ride. On the one hand there is the imminent patent expiry of Lantus in 2015.
Related articles »  
Sanofi SA (ADR) (NYSE:SNY) In For Interesting Times
Boston, MA, 03/31/2014 (usastockreports)- Sanofi SA (ADR) (NYSE:SNY) seems to be in for a bumpy ride. On the one hand there is the imminent patent expiry of Lantus in 2015.
Stocks in the Spotlight - Edwards Lifesciences Corp(NYSE:EW), Sanofi SA (ADR ...
Las Vegas, NV - April 14, 2014 - (Tech Sonian) - Edwards Lifesciences Corp(NYSE:EW) recently declared that the U.S. District Court for the District of Delaware granted a preliminary injunction limited the sale of Medtronic's CoreValve system in the ...
Related articles »  
Notable Movers - Sanofi SA (ADR) (NYSE:SNY), Thermo Fisher Scientific Inc ...
Las Vegas, NV - 07 April 2014 - (Tech Sonian) - Sanofi SA (ADR) (NYSE:SNY) declared that the U.S. Food and Drug Administration (FDA) has expanded the approved age indication of Adacel� (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular ...
Even simple pregnancy tests can run into problems
Providing a superb example of the ever-changing biomedical landscape for even the most mundane of diagnostics, researchers at Washington University School of Medicine find that some commonly-used urine pregnancy tests lose their negative predictive ...
Related articles »  
Can Once Daily GLP-1 Lyxumia Be The Next Major Growth Driver For Sanofi?
Lyxumia (lixisenatide) for the treatment of type 2 diabetes is once-daily GLP-1 from Sanofi's (SAN) stable. It is a potential head to head competitor to Novo Nordisk's (NVO) Victoza ($2.1b - 2013 annual sales).
NYSE unusual Volume: Sanofi SA (NYSE:SNY), Hawaiian Electric Industries ...
Sanofi SA (ADR) (NYSE:SNY) seems to be in for a bumpy ride. On the one hand there is the imminent patent expiry of Lantus in 2015.
Healthcare Active runners: Teva Pharmaceutical Industries (NYSE:TEVA ...  Tech News
Related articles »  
Notable Stocks: Xenith Bankshares (NASDAQ:XBKS), Sanofi SA (NYSE:SNY ...
Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients' needs.
Related articles »  
Investor's Alert � Insulet Corporation (NASDAQ:PODD), Hospira, Inc. (NYSE ...
Sanofi SA (ADR) (NYSE:SNY) posted that the U.S. FDA has enlarged the permitted age indication of Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Tdap) for active booster immunization for the prevention of ...
Related articles »  
Large Cap Unusual Volume: TD Ameritrade Holding (NYSE:AMTD), Anadarko ...
Sanofi SA (ADR) (NYSE:SNY) is so confident that it has already spent EUR 300 million at a facility near Lyon, France and has started producing the drug since July 2013, and is ready to sell from late 2015 subject to regulatory approval.